Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir

References

• World Health OrganizationGlobal alert and response: hepatitis C Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.htmlAccessed December 2, 2010
   Google Scholar
• ShiratoriYImazekiFMoryiamaMHistologic improvement of fibrosis in patients with hepatitis C who have sustained virological response to interferon therapyAnn Intern Med200013251752410744587
   PubMed Web of Science ®Google Scholar
• YoshidaHArakawaJSataMInterferon therapy prolonged life expectancy among chronic hepatitis C patientsGastroenterology200212348349112145802
   PubMed Web of Science ®Google Scholar
• ShiratoriYItoYYokosukaOAntiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survivalAnn Intern Med200514210511415657158
   PubMed Web of Science ®Google Scholar
• RinconDRipollCLo IaconoOAntiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosisAm J Gastroenterol20061012269227417032192
   PubMed Web of Science ®Google Scholar
• BrunoSStroffoliniTColomboMSustained virological response to Interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective studyHepatology20074557958717326216
   PubMed Web of Science ®Google Scholar
• VeldtBJHeathcoteEJWedemeyerHSustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosisAnn Intern Med200714767768418025443
   PubMed Web of Science ®Google Scholar
• BrunoSCrosignaniAFacciottoCSustained virological response prevents the development of esophageal varices in compensated, Child-Pugh class A HCV-induced cirrhosis. A twelve-year prospective follow-up studyHepatology2010512069207620196120
   PubMed Web of Science ®Google Scholar
• CardosoACMoucariRFigueiredo-MendesCImpact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosisJ Hepatol20105265265720346533
   PubMed Web of Science ®Google Scholar
• D’AmbrosioRAghemoARumiMGThe course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapyAntivir Ther20111667768421817189
   PubMed Web of Science ®Google Scholar
• MannsMPMcHitchisonJGGordonSCPeginterferon-alfa2b plus ribavirin compared with interferon-alfa2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trialLancet200135895896511583749
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRPeginterferon-alfa2a plus ribavirin for chronic hepatitis C infectionN Engl J Med200234797598212324553
   PubMed Web of Science ®Google Scholar
• HadziyannisSJSetteHMorganTRPeginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern Med200414034635514996676
   PubMed Web of Science ®Google Scholar
• McHutchisonJGEversonGTGordonSCTelaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infectionN Engl J Med20093601827183819403902
   PubMed Web of Science ®Google Scholar
• HézodeCForestierNDusheikoGTelaprevir and peginterferon with or without ribavirin for chronic HCV infectionN Engl J Med20093601839185019403903
   PubMed Web of Science ®Google Scholar
• McHutchisonJGMannsMPMuirAJTelaprevir for previously treated chronic HCV infectionN Engl J Med20103621292130320375406
   PubMed Web of Science ®Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic hepatitis C infectionN Engl J Med20113642405241621696307
   PubMed Web of Science ®Google Scholar
• ShermanKEFlammSLAfdhalNHResponse-guided telaprevir combination treatment for hepatitis C virus infectionN Engl J Med20113651014102421916639
   PubMed Web of Science ®Google Scholar
• ZeuzemSAndreonePPolSTelaprevir for retreatment of HCV infectionN Engl J Med20113642417242821696308
   PubMed Web of Science ®Google Scholar
• PawlotskyJMChevaliezSMcHutchisonJGThe hepatitis C virus life cycle as a target for new antiviral therapiesGastroenterology20071321979199817484890
   PubMed Web of Science ®Google Scholar
• RongLPerelsonALTreatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modellingCrit Rev Immunol20103013114820370626
   PubMed Web of Science ®Google Scholar
• BühlerSBartenschlagerRNew targets for antiviral therapy of chronic hepatitis CLiver International20123291622212566
   PubMed Web of Science ®Google Scholar
• LangeCMSarrazinCZeuzemSReview article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapyAliment Pharmacol Ther201032142820374226
   PubMed Web of Science ®Google Scholar
• ReeskinHWZeuzemSWeeginkCJRapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized studyGastroenterology2006131997100217030169
   PubMed Web of Science ®Google Scholar
• PratiGMAghemoARumiMGHyporesponsiveness to PegIFNα2b plus ribavirin in patients with hepatitis C-related advanced fibrosisJ Hepatol20125634134721756847
   PubMed Web of Science ®Google Scholar
• LangeCMZeuzemSIL28B single nucleotide polymorphism in the treatment of chronic hepatitis CJ Hepatol20115569270121440591
   PubMed Web of Science ®Google Scholar
• SarrazinCSchwendySMöllerBImproved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24–72 weeksGastroenterology20111411656166421784046
   PubMed Web of Science ®Google Scholar
• AghemoADegasperiEColomboMDirectly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trialsDig Liver Dis2012
   Google Scholar
• PoynardTColomboMBruixPeginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapyGastroenterology20091361618162819208349
   PubMed Web of Science ®Google Scholar
• ShiffmanMLDi BisceglieAMLindsayKLPeginterferon-alfa2a and ribavirin in patients with chronic hepatitis C who have failed prior treatmentGastroenterology20041261015102315057741
   PubMed Web of Science ®Google Scholar
• ForestierNZeuzemSTriple therapy with Telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-respondersLiver Int201232Suppl 1445022212571
   PubMed Web of Science ®Google Scholar
• BedossaPPoynardTAn algorithm for the grading of activity in chronic hepatitis CHepatology1996242892938690394
   PubMed Web of Science ®Google Scholar
• HèzodeCDorivalCZoulimFSafety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic nonresponders. First results of the French early access program (ANRS CO20-CUPIC) in real-life settingPresented at the French national liver meetingParis, FranceSeptember 28–October 1, 2011
   Google Scholar
• SulkowskiMReddyKRAfdhalNHAnemia has no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in ADVANCE and ILLUMINATE phase 3 studiesJ Hepatol201154S195
   Web of Science ®Google Scholar
• RongLDahariHRibeiroRMPerelsonASRapid emergence of protease inhibitor resistance in hepatitis C virusSci Transl Med201023032
   Web of Science ®Google Scholar
• ForestierNReesinkHWWeeginkCJAntiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CHepatology20074664064817879366
   PubMed Web of Science ®Google Scholar
• SarrazinCKiefferTLBartelsDDynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevirGastroenterology20071321767177717484874
   PubMed Web of Science ®Google Scholar
• KiefferTLSarrazinCMillerJSTelaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsHepatology20074663163917680654
   PubMed Web of Science ®Google Scholar
• SusserSVermehrenJForestierNAnalysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevirJ Clin Virol20115232132721924672
   PubMed Web of Science ®Google Scholar
• eMedFusion, The University of LiverpoolHep Drug Interactions Available from: http://www.hep-druginteractions.orgAccessed Jun 28, 2012
   Google Scholar
• ThompsonAJMuirAJSulkowskiMSInterleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusGastroenterology201013912012920399780
   PubMed Web of Science ®Google Scholar
• JacobsonIMCatlettIMarcellinPTelaprevir substantially improved SVR rates across all IL28B genotypes in the advance trialJ Hepatol201154S543
   Web of Science ®Google Scholar
• Martinot-PeignouxMMaylinSMoucariRVirological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirinAntivir Ther20091450151119578235
   PubMed Web of Science ®Google Scholar
• FriedMWHadziyannisSJShiffmanMLMessingerDZeuzemSRapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infectionJ Hepatol201155697521145856
   PubMed Web of Science ®Google Scholar
• FosterGZeuzemSAndreonePSubanalysis of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorizationJ Hepatol201154Suppl 16A20951458
   PubMed Web of Science ®Google Scholar
• Prise de position de l’Association Française pour l’Etude du Foie (AFEF) sur les trithérapies (Peg-IFN + ribavirine + inhibiteur de protéase) dans la prise en charge des malades atteints d’hépatite chronique C.
   Google Scholar
• Referensgruppen för Antiviral Terapi (Rav)Läkemedelsbehandling av hepatit C virusinfektion hos vuxna och barn – uppdaterad rekommendationSwedish Consensus Guidelines2011
   Google Scholar
• SarrazinCBergTCornbergMExpertenempfehlungen zur Triple-Therapie der HCV Infektion mit Boceprevir und TelaprevirZ Gastroenterol201149116
   Google Scholar